November 2015

PharmaTutor
5 November 2015

Work as Pharmacist in District Selection Committee, Pune

Application are invited for the post of Pharmacist under District council Pune.

Post: Pharmacist

[adsense:336x280:8701650588]

No.of post: 01

5 November 2015
Research position in INCLEN project on Neonatal Pneumonia at Manipal University

Manipal University is synonymous with excellence in higher education. Over 28,000 students from 57 different nations live, learn and play in the sprawling University town, nestled on a plateau in Karnataka’s Udupi district. It also has nearly 2500 faculty and almost 10000 other support and service staff, who cater to the various professional institutions in health sciences, engineering, management, communication and humanities which dot the Wi-Fi-enabled campus.

5 November 2015
Job as Clinical Res Associate in Unilever

Every day, around the world, people reach for Unilever products. Our brands are trusted everywhere and, by listening to the people who buy them, we've grown into one of the world's most successful consumer goods companies. In fact, 150 million times a day, someone somewhere chooses a Unilever product.

5 November 2015
Application are invited for Scientist in NBRC

Applications are invited for the position of Scientist ‘C’ (Project) in the laboratory of Prof. Pravat K. Mandal at National Brain Research Centre, Manesar, India. The primary scientific interest of the lab is to identify early in vivo biomarkers for neurodegenerative disorders, particularly Alzheimer’s disease. The lab uses multi-modal neuroimaging techniques, i.e.

Mylan N.V. (NASDAQ: MYL) announced the U.S. Federal Trade Commission ("FTC") has cleared the company's proposed transaction to acquire Perrigo Company plc (NYSE: PRGO; TASE) subject to Mylan's divestiture of certain products following the consummation of the offer. The FTC clearance represents the final regulatory clearance needed by Mylan to close its acquisition of Perrigo and represents the last remaining condition that needs to be satisfied for the successful completion of the offer other than the acceptance condition.

Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto Prime in Europe. Its active ingredient flupyradifurone, which belongs to the chemical class of butenolides, has been approved for the maximum time span of 10 years by the European Commission in accordance with Regulation (EC) 1107/2009.  The first national registrations of Sivanto prime in European countries are expected in 2016 and the market introduction is planned for 2017.

Bristol-Myers Squibb company (BMY) and Cardioxyl Pharmaceuticals, Inc. announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the issued and outstanding capital stock of Cardioxyl, a private biotechnology company focused on the discovery and development of novel therapeutic agents for the treatment of cardiovascular disease. The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in Phase 2 clinical development as an intravenous treatment for acute decompensated heart failure (ADHF). 

The transaction includes upfront and near-term milestone payments of up to 300 million and potential additional consideration of up to USD1.775 billion upon the achievement of certain development, regulatory and sales milestones.

CXL-1427 releases nitroxyl, a molecule that has demonstrated beneficial effects on heart muscle and vascular function. Pre-clinical and early clinical data indicate that CXL-1427 improves how the heart muscle contracts and relaxes without increasing heart rate or the demand for oxygen. Current therapies for ADHF that improve heart muscle function produce an increase in heart rate and/or oxygen consumption, and are associated with an increased risk for ischemia, arrhythmias and increased mortality.

“The acquisition of Cardioxyl strengthens Bristol-Myers Squibb’s heart failure pipeline with a Phase 2 asset that has the potential to change the course of the disease rather than simply treating the symptoms,” said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb. “Bristol-Myers Squibb is uniquely positioned, with our understanding of patient needs in the hospital setting and our heritage in cardiovascular diseases, to continue development of CXL-1427 as a potential new therapy to address the clinical and economic burden of heart failure.”


“We are excited about the breadth of drug development capabilities and cardiovascular expertise that Bristol-Myers Squibb will bring to the nitroxyl donor program,” said Christopher A. Kroeger, M.D., President and Chief Executive Officer, Cardioxyl. “Heart failure is an important and under-served therapeutic area and we believe Bristol-Myers Squibb is the optimal partner to bring new therapeutic options to the patients who need them.”

<< Pharma News


Subscribe to PharmaTutor News Alerts by Email >>

Boehringer Ingelheim announced at the BIO-Europe® conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and safety of BI 1482694 (HM61713) in patients with T790M mutation-positive non-small cell lung cancer (NSCLC), whose tumours stopped responding to currently available epidermal growth factor receptor (EGFR) directed therapies. The primary endpoint of this trial, which is the first in a broad clinical development programme for BI 1482694, is objective response rate (ORR).

[adsense:336x280:8701650588]

5 November 2015
Career for Junior Research Fellow in BITS Pilani | M.Pharm

The Pharmacy department of BITS Pilani is one of the few early schools of Pharmacy in India. Established in 1950, under the able leadership of (Late) Prof. M. L. Schroff, Father of Pharmacy Education in India, it blossomed into one of the most sought after Schools of Pharmacy in India due to its broad-based education system and university-industry linkages, which is the hallmark of BITS, Pilani. In the year of 2011, the Department of Pharmacy has completed 60 years of its existence as a premier institution in the field of Pharmacy Education and Research in India and abroad. Alumni are well placed in India as well as abroad in various pharmaceutical companies, government organizations like drug control, research laboratories, etc., and in several well-known academic institutions.

Applications are invited from the eligible candidates to work as Junior Research Fellow (JRF) in Department of Science and Technology (DST) SERB sponsored project under Dr. Paul Atish Tulshiram at Department of Pharmacy,  BITS Pilani, Pilani Campus.

Post: Junior Research Fellow (JRF)

Nestle India said the "masala" version of Maggi noodles will hit the retail shelves as early as this month, having cleared all the tests ordered by the Bombay High Court at three accredited laboratories.